COMMUNIQUÉS West-GlobeNewswire

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
10/11/2025
Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome ( GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; [...]
Health Catalyst Reports Third Quarter 2025 Results
10/11/2025
SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]
FibroGen Reports Third Quarter 2025 Financial Results and Provides Business Update
10/11/2025
Completed the sale of FibroGen China to AstraZeneca for approximately $220 million Initiated the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in [...]
Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update
10/11/2025
Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab/semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment; the data demonstrated a clean [...]
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
10/11/2025
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B- [...]
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
10/11/2025
WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases [...]
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control [...]
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025) Pending the results of the topline data from the HOPE-3 [...]
Mereo BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Highlights
10/11/2025
Data from Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta on-track for around the end of 2025 Cash of $48.7 million as of September 30, 2025, expected to support operations into 2027 LONDON, [...]
NeXtGen Biologics and Lovell® Government Services Partner to Bring Innovative Advanced Wound Care Technology to Federal Healthcare Systems
10/11/2025
PENSACOLA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lovell ® Government Services and NeXtGen™ Biologics, Inc., a medical device company that manufactures NeoMatriX ® , announced today that they have partnered to serve [...]
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
10/11/2025
Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated [...]
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
10/11/2025
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled [...]
Idorsia’s aprocitentan improved key prognostic indicators in patients with difficult-to-control hypertension
10/11/2025
New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel [...]
HHS Advances Women’s Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy
10/11/2025
Washington, D.C., Nov. 10, 2025 (GLOBE NEWSWIRE) -- The U.S. Department of Health and Human Services (HHS) today announced historic action to restore gold-standard science to women’s health. After more than two decades [...]
Glaucoma 360 2026: Where Science, Innovation, and Collaboration Shape the Future of Vision
10/11/2025
Annual event accelerates progress toward curing glaucoma, from groundbreaking research to emerging therapies SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation (GRF) today announced the 15th [...]
NTG Nordic Transport Group publishes interim report for Q3 2025
10/11/2025
Company announcement no. 10 – 25 10 November 2025 NTG Nordic Transport Group publishes interim report for Q3 2025 The interim report for Q3 2025 is enclosed. In connection with publication of the results for Q3 2025, a [...]
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes
10/11/2025
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market and other [...]
Booking Health Announces Expanded Access to Stage 4 Lung Cancer Treatments During Lung Cancer Awareness Month
10/11/2025
Stage 4 Lung Cancer Langenfeld, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Booking Health , a global facilitator of international medical care, announced today a timely initiative aimed at improving access to advanced [...]
ACTG Presents SLIM LIVER Findings at AASLD Liver Meeting Demonstrating Improvements in Biomarkers of Cardiovascular Risk among People Living with HIV and MASLD Who Receive Semaglutide
10/11/2025
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced data finding that treating people living with HIV and metabolic [...]

Pages